P170016/S001: SYNOJOYNT
FDA’s recorded scope: Approval for the replacement and relocation of the blistering and labeling equipment and minor change to process and size of label.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Mesoblast. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 23, 2025 to Dec 23, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MOZ appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P170016, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: Level 38, 55 Collins St., Melbourne, 3000. Recorded on P170016/S001, decision dated Dec 23, 2025.
FDA’s recorded scope: Approval for the replacement and relocation of the blistering and labeling equipment and minor change to process and size of label.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SYNOJOYNTP170016/S001 | Mesoblast | PMA supplement | Dec 23, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.